Breaking News
Get 40% Off 0
💰 Buffett reveals a $6.7B stake in Chubb. Copy the full portfolio for FREE with InvestingPro’s Stock Ideas tool Copy Portfolio
Close

Neumora Therapeutics Inc (NMRA)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Neumora Therapeutics's earnings

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
9.67 +0.04    +0.42%
17/05 - Closed. Currency in USD ( Disclaimer )
After Hours
9.67
-0.00
-0.00%
16:01:38 - Real-time Data
  • Volume: 320,321
  • Bid/Ask: 0.00 / 0.00
  • Day's Range: 9.38 - 9.70
Type:  Equity
Market:  United States
Neumora Therapeutics 9.67 +0.04 +0.42%

Neumora Therapeutics Inc Company Profile

 
Get an in-depth profile of Neumora Therapeutics Inc, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

124

Equity Type

ORD

Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer’s disease; and NMRA-266, which is in the phase 1 clinical trial for the treatment of schizophrenia and other neuropsychiatric disorders. In addition, its preclinical phase product includes NMRA-NMDA for the treatment of schizophrenia; NMRA-CK1d, a CK1d inhibitor program for the treatment of amyotrophic lateral sclerosis; NMRA-NLRP3 for the treatment of certain neurodegenerative conditions; and NMRA-GCase for the treatment of Parkinson’s disease. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. Neumora Therapeutics, Inc. was incorporated in 2019 and is headquartered in Watertown, Massachusetts.

Contact Information

Address 490 Arsenal Way Suite 200
Watertown, 02472
United States
Phone 857 760 0900
Fax -

Top Executives

Name Age Since Title
Gaurav Singal - - Member of Technology Advisory Board
Patrick Sullivan - - Member of Scientific Advisory Board
Kristina M. Burow 51 2020 Independent Director
Diego A. Pizzagalli - - Member of Technology Advisory Board
John D. Murray - - Member of Technology Advisory Board
Sandeep Robert Datta - - Member of Scientific Advisory Board
Andrew Trister - - Member of Technology Advisory Board
Mark Daly - - Member of Scientific Advisory Board
Richard Huganir - - Member of Scientific Advisory Board
Iain McFadyen - - Member of Technology Advisory Board
Edward Roberts - - Member of Scientific Advisory Board
Benjamin Neale - - Member of Scientific Advisory Board
John Krystal - - Member of Scientific Advisory Board
Maykin Ho 71 2021 Independent Director
Alex Wiltschko - 2023 Member of Technology Advisory Board
Hugh Rosen 65 - Member of Scientific Advisory Board
Beth Stevens - - Member of Scientific Advisory Board
Alan Anticevic - - Member of Technology Advisory Board
Paul L. Berns 57 2020 Co-Founder & Executive Chairman
Matthew K. Fust 59 2020 Independent Director
Bernardo L. Sabatini - - Member of Scientific Advisory Board
David A. Piacquad 67 2023 Independent Director
Morgan H. Sheng 66 - Member of Scientific Advisory Board
Alaa Halawa 41 2022 Independent Director
Edward M. Scolnick 83 - Member of Scientific Advisory Board
Henry O. Gosebruch 51 2023 President, CEO & Director
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

NMRA Comments

Write your thoughts about Neumora Therapeutics Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email